Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (1366)	2/14/2001 3:33:42 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 1826

MGI Pharma Results -3: Street Yr Loss View 68c/Shr MOGN Dow Jones Newswires MGI Pharma Inc. (MOGN) said it expects a loss of $35 million to $45 million for the year ending Dec. 31, 2001. A First Call/Thomson Financial survey of four analysts expected the pharmaceutical company to lose 68 cents a share in 2001. The company anticipates product sales growth of 10% to 15% in 2001, while expecting cost of product sales as a percent of sales revenue to range from 10% to 15%. MGI Pharma sees an amortization expense in 2001 of about $1.2 million in 2001 as a result of acquiring Hexalun Capsules. Jim